Key statistics
As of last trade Arcus Biosciences Inc (RCUS:NYQ) traded at 20.94, -20.68% below its 52-week high of 26.40, set on Dec 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 21.06 |
|---|---|
| High | 21.02 |
| Low | 20.59 |
| Bid | 20.92 |
| Offer | 20.96 |
| Previous close | 21.13 |
| Average volume | 876.47k |
|---|---|
| Shares outstanding | 122.86m |
| Free float | 85.89m |
| P/E (TTM) | -- |
| Market cap | 2.60bn USD |
| EPS (TTM) | -3.43 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 18:25 GMT.
More ▼
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
- Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Biosciences to Participate in Two Upcoming Investor Conferences
More ▼
